Kornimate/medical-research-clean huggingface dataset:
analysis of urinary methylation patterns via liquid biopsy as an early diagnosis tool

Conditions: Bladder Cancer

Summary: multicenter, observational, prospective, biological pilot study on liquid biopsy, aimed at investigating methylation profiles in relation to the early diagnosis of bladder cancer, to validate the potential of commercially available tests (e.g. bladdercare, bladder epicheck), to apply and validate tests based on targeted multi-marker or genome wide analyzes via ngs and to identify methylation profiles as a tool to infer clinical outcome.

the study has the primary objective to investigate the diagnostic capacity of methylation levels in urine samples, furthermore it has the secondary objective of applying an ngs test on the urine sample capable of evaluating the highest methylation levels comprehensive, with better analytical performance than the currently available standard on the market, leveraging targeted sequencing of multiple genes or global analysis of the whole methylome. to describe the diagnostic performance of the methods in a real-world clinical environment and identify the characteristic methylation profiles capable of stratifying patients with different prognoses, and finally to explore the potential economic impact of applying such tests as tools alternatives to conventional practices.

Eligibility criteria:
inclusion criteria: patient group * age ≥ 18 years * proven diagnosis of bladder cancer (infiltrating muscle or non-infiltrating muscle) * performance status (ps) 0-1 * ability to follow the procedures established by the study * written consent for participation in the study and data processing group of healthy subjects * age ≥ 18 years * ability to follow the procedures established by the study * written consent for participation in the study and data processing exclusion criteria: patient group * presence of metastatic bladder cancer * lack of autonomy in following the procedures established by the study group of healthy subjects * previous or current clinical history associated with bladder cancer * diagnostic suspicion associated with tumor pathologies * ongoing or previous systemic oncological treatments * presence of inflammatory and/or autoimmune diseases related to particular conditions potentially modifying the methylation profile * existing pharmacological treatments (and/or any other type of treatment) that could alter the results of the analyzes conducted for the present study * lack of autonomy in following the procedures established by the study

Keywords: methylation levels in urine samples
china registry for genetic / metabolic liver diseases

Conditions: Genetic/Metabolic Liver Diseases

Summary: cr-gmld registry started on june 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland china. demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. patients' whole blood and serum were collected for genetic testing and future researches. these patients will be followed-up every six to twelve months.

this web-based database was launched on june 13, 2015 and consists of tertiary or secondary hospitals with special interest and expertise on managing genetic/metabolic liver diseases patients across mainland china. the main inclusion criteria for this registration are patients who were diagnosed or possibly diagnosed with wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases. at the first time of data entry, demographics, medical history, biochemistry and hematology results, radiology reports, diagnosis and treatment information were recorded. patients' whole blood and serum were collected for molecular genetic testing and future researches. then the registered patients will receive standard of care and be followed-up every 6 to 12 months. on each visit, biochemical, radiological reports, as well as clinical progress were recorded.

Eligibility criteria:
inclusion criteria: patients who were diagnosed or possibly diagnosed with wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases. exclusion criteria: patients who are unable or unwilling to provide informed consent.

Keywords: wilson's disease hereditary hemochromatosis hereditary hyperbilirubinemias inherited cholestatic liver disease genetic testing
options for navigating talking about risk and adolescent choices

Conditions: Substance Use (Drugs, Alcohol); Substance Use Risk; Substance Use; Emotion Regulation; Risk Reduction Behavior; Risk Reduction

Summary: this study will examine the effectiveness of on-trac (options for navigating talking about risk and adolescent choices), which is an online substance use prevention program that also teaches emotion regulation skills. 200 adolescents, 12-15 years of age, will be randomized to on-trac or a wait list comparison group (who will be offered the intervention at the end of their study participation) to determine impact on substance use, emotion regulation abilities, mental health symptoms, and other risk behavior outcomes.


Eligibility criteria:
inclusion criteria: * contact with the rhode island child welfare system * caregiver who is a parent/guardian of a child who experienced maltreatment * caregiver who speaks english or spanish * caregiver who does not have developmental delays * adolescent who is between 12-15 years of age * adolescent who is fluent in english * adolescent who has active follow-up with the rhode island child welfare system due to an indicated finding of abuse or neglect in the past year exclusion criteria: * adolescent who cannot read at a 4th grade level * adolescent who has a sibling who has participated in the program * adolescent who has developmental delays * adolescent who lacks parental consent for the study

Keywords: adolescent substance use emotion regulation risk reduction
systemic amoxicillin plus metronidazole in peri-implantitis treatment

Conditions: Peri-implantitis; Periodontal Diseases

Summary: the primary objective of this controlled clinical trial is to evaluate the clinical effect of systemic amoxicillin plus metronidazole therapy in conjunction with initial non-surgical treatment of peri-implantitis. the secondary objective is to assess the microbiological effectiveness of this peri-implantitis treatment approach. the present study is a single-blind, randomized controlled clinical trial. adult patients with at least one endosseous implant in the oral cavity with clinical and radiographical evidence of periimplantitis will be included in this study. patients with implants affected by peri-implantitis will receive initial periodontal treatment existing of oral hygiene instructions and mechanical cleansing of both implants and remaining dentition. immediately after initial periodontal therapy patients will be instructed to rinse their mouth with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds for 2 weeks. additionally patients will receive a recipe for medication consisting of 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for the following 7 days or no recipe. the main study parameter is the mean peri-implant bleeding score.


Eligibility criteria:
inclusion criteria: * the patient is ≥ 18 years of age; * the patient has at least one endosseous implant in the oral cavity with clinical and radiographical signs of peri-implantitis. peri-implantitis is defined as a loss of marginal bone ≥ 2 mm as compared to the shoulder of the implant (the level at which the bone is normally located immediately after implant placement), in combination with bleeding and/or suppuration on probing and a peri-implant probing depth ≥ 5 mm; * the implants have been in function for at least two years; * the patient is capable of understanding and giving informed consent. exclusion criteria: * medical and general contraindications for the surgical procedures; * a history of local radiotherapy to the head and neck region; * pregnancy and lactation; * uncontrolled diabetes (hba1c \< 7% or \< 53 mmol/mol) * mononucleosis infectiosa * organic neurological disorders * use of antibiotics during the last 3 months; * known allergy to amoxicillin, metronidazole or chlorhexidine; * long-term use of anti-inflammatory drugs; * full edentulism (no remaining teeth, only implants) * incapability of performing basal oral hygiene measures as a result of physical or mental disorders; * implants placed in areas augmented with autogenous bone from the crista iliac region; * implants placed in skin grafted areas; * implants with bone loss exceeding 2/3 of the length of the implant or implants with bone loss beyond the transverse openings in hollow implants; * implant mobility; * implants at which no position can be identified where proper probing measurements can be performed; * previous surgical treatment of the peri-implantitis lesions; * previous non-surgical treatment of the peri-implantitis lesions during the last 6 months (scaling or curettage)
study of colchicine to prevent the postpericardiotomy syndrome

Conditions: Postpericardiotomy Syndrome

Summary: the purpose of the study is to determine whether colchicine is safe and effective in the prevention of the postpericardiotomy syndrome.

the postpericardiotomy syndrome is a frequent complication after cardiac surgery affecting from 20 to 40% of patients. the etiology of this complication is a subject of debate. it is commonly believed to be an autoimmune response to pericardial and/or pleural bleeding or surgical trauma. colchicine is safe and effective in the treatment and prevention of pericarditis and preliminary data have shown that it may be effective also in the primary prevention of the postpericardiotomy syndrome. comparisons: the study will compare the safety and efficacy of colchicine in the primary prevention of the postpericardiotomy syndrome in addition to optimal standard care.

Eligibility criteria:
inclusion criteria: * patients in the third day after a cardiac surgery operation * age≥ 18 years * informed consent exclusion criteria: all evaluated before the surgical operation: * known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality * serum creatinine \>2.5 mg/dl * serum creatine kinase (ck) over the upper limit of normality or known myopathy * known gastrointestinal or blood disease * pregnant or lactating women or women not protected by a contraception method * known hypersensibility to colchicine * treatment with colchicine at enrolment

Keywords: postpericardiotomy syndrome pericarditis prevention colchicine recurrence
clinical characteristics and outcome of covid-19 infection in patients with chronic respiratory diseases.

Conditions: Covid19; Chronic Respiratory Disease

Summary: 1. to identify the pattern of presentation of covid-19 in patients with chronic respiratory diseases 2. to asses the severity of covid-19 in patients with chronic respiratory diseases 3. to identify the outcome of covid-19 in patients with chronic respiratory diseases

genomes analysis reveal that sars-cov-2 presents unique features: optimal affinity for angiotensin converting enzyme 2 (ace2) receptor and a polybasic cleavage site at the s1/s2 spike junction that determines infectivity and host range \[3-4) patients with sars-cov-2 infection may present symptoms ranging from mild to severe with a large portion of the population being asymptomatic carriers. the most common reported symptoms include fever (83%), cough (82%) and shortness of breath (31%) \[5-6\]. patients suffering from chronic respiratory diseases (crd) such as chronic respiratory failure, asthma, chronic obstructive pulmonary disease (copd), interstitial lung diseases (ild), pulmonary hypertension (ph), sarcoidosis or cystic fibrosis (cf), were immediately considered to be at risk of severe forms of covid-19 \[7\]. indeed, covid-19 is responsible for various respiratory symptoms, from cough with dyspnea to acute respiratory distress syndrome (ards) in its most severe presentation \[8-9\]. in parallel, it has been shown that covid-19 patients have an increased risk of venous thromboembolic disease \[10\]. there is concern that the respiratory complications of covid-19 could be deleterious in patients with prior crd. \[11-12-13\] during covid-19 pandemic, studies mostly demonstrated that copd was related with worse outcomes. there may be a few reasons why the course of covid-19 in copd patients has been worse. firstly, copd patients tend to be older and have more comorbidities which may increase covid-19 severity \[14\]. respiratory failure and hypoxemia, which are the most important causes of death in covid-19 patients, are more common in copd patients \[15\]. although the exact mechanism of acute exacerbation of ild is not fully understood, the current belief is that it can be caused by numerous triggers, including infection, or it can be idiopathic.(16) it is likely that respiratory infection with covid-19 could trigger an exacerbation of underlying ild and result in poor outcomes. there is similar concern regarding the possibility of exacerbation in patients with sarcoidosis, especially those with fibrotic manifestations.(17) 1. to identify the pattern of presentation of covid-19 in patients with chronic respiratory diseases 2. to asses the severity of covid-19 in patients with chronic respiratory diseases 3. to identify the outcome of covid-19 in patients with chronic respiratory diseases

Eligibility criteria:
inclusion criteria: 1. patients with chronic respiratory diseases diagnosed with covid-19 infection by pcr 2. patients aged 18 years and above exclusion criteria: 1. patient aged below 18 years old. 2. patients refuse to share in our study
retinal neurodegenerative signs in alzheimer's diseases

Conditions: Alzheimer's Disease

Summary: a few studies suggest that patients suffering from neurodegenerative diseases (such a multiple sclerosis or alzheimer's disease (ad)) show decreased thickness of the retinal nerve fiber layer (rnfl), indicating axonal degeneration. high-definition spectral domain optical coherence tomography (sd-oct), performed without radiation in a few seconds per eye, offers a precise and standardized estimation of this parameter, which could constitute a biomarker for cerebral axonal degeneration. these rnfl deficits might even be the earliest sign of ad, prior to damage of the hippocampal region that impacts memory. besides, some associations of ad with some degenerative diseases of the eye (glaucoma, microvascular abnormalities, age-related macular degeneration (amd)) have also been reported. it therefore seems interesting to determine whether rnfl thickness, and other ocular parameters, may give some indications for a better detection of ad and cognitive decline in the elderly.


Eligibility criteria:
inclusion criteria: * inclusion criteria for ad cases: * diagnosis of probable ad, defined according to the nincds-ardra criteria51 * light to moderate severity of the disease, defined by a mmse score \>10 (global evaluation of cognition) * patient aged 50 years or more * patient benefiting from social insurance inclusion criteria for controls: * absence of suspicion of dementia, based on normal performance according to age and educational level at neuropsychological testing defined as: * free recall ≥17 and total recall ≥40 for the free and cued selective reminding test (grober and buschke test 52) mmse ≥ norm for age and educational level (defined by mean - 1 sd) * isaac's set test ≥ norm for age and educational level (defined by mean - 1 sd) * matched to age and gender of the cases * patient benefiting from social insurance exclusion criteria: exclusion criteria for all patients : * history of parkinson's disease or other neurodegenerative disorder * history of horton's disease * history of inflammatory neuropathies (in particular devic's disease, multiple sclerosis) * history of vascular ischemic neuropathies and chronic intracranial hypertension * history of pituitary tumors * presence of diseases (systemic and/or ocular diseases) or behavioural or cognitive symptoms incompatible with eye examination * known diabetes * person under tutorship or curatorship, person unable to express consent additional exclusion criteria for ad cases: * dementia of other cause than ad * severe ad, defined by mmse score ≤ 10 additional exclusion criteria for controls: * presence of dementia, of whatever cause

Keywords: retina alzheimer's disease neurodegenerative signs
a study of the natural progression of interstitial lung disease (ild)

Conditions: Interstitial Lung Diseases; Idiopathic Pulmonary Fibrosis; Sarcoidosis; Connective Tissue Disorder

Summary: we propose to acquire data and blood samples on all patients being cared for by the interstitial lung disease (ild) program. additionally, we will collect data and blood samples from a control group for comparator purposes. in doing so, we will be able to describe the "phenotypic" expression of these diseases.


Eligibility criteria:
inclusion criteria: * interstitial lung disease exclusion criteria: * does not have interstitial lung disease

Keywords: interstitial lung diseases idiopathic pulmonary fibrosis sarcoidosis mrna and cytokine expression
selenium treatment in autoimmune thyroiditis (ait)

Conditions: Autoimmune Thyroiditis; Hashimotos Thyroiditis

Summary: selenium suppresses autoimmune destruction of thyrocytes and decreases titers of serum tpoab in ait patients. older 4 clinical trials approved the efficacy of the daily dose of 200micg. it's believed that se saturates the deficient stores of gpx so gpx saves the thyrocytes against to oxidative stresses. although less than 70 micg/d is sufficient to maximize gpx activity, none of the authors tested the doses less than 200 micg/d. our hypothesis was that if 100 micg/d can not suppress the tpoab titers,it means autoimmune destruction can not be blocked by saturation of deficient stores of gpx solely and the mechanism of action requires more than repletion of deficient stores. it's important not only to estimate the optimal dose but to understand the mechanism of action. high dose therapy may also suppress tpoab levels in se-non-deficient ait patients, if it is so, se therapy may becomes the solely treatment modality which can suppress the autoimmunity in more than 400 million ait patients. because there've been no way to suppress autoimmune war and replacement of lt4 had been the only treatment modality for palliation. an other independent part of the study is to test the effect of se in adolescent ait patients.


Eligibility criteria:
inclusion criteria: * clinically approved ait patients who do not use any medication other than lt4 to keep tsh in the lower half of normal range. exclusion criteria: * any kind of drug use other than lt4 or any kind of known pathology which may effect gis absorption.

Keywords: thyroiditis autoimmune hashimoto's tpoab selenium
umbilical cord mesenchymal stem cells infusion via hepatic artery in cirrhosis patients

Conditions: Liver Cirrhosis; Radiology; Mesenchymal Stem Cells; Umbilical Cord

Summary: the purpose of this study is to investigate the efficacy of umbilical cord mesenchymal stem cells (mscs) infusion via hepatic artery in the treatment of liver cirrhosis.

to investigate the efficacy of umbilical cord mesenchymal stem cells (mscs) infusion via hepatic artery in the treatment of liver cirrhosis. patients with liver cirrhosis were randomly separated into two groups. umbilical cord mscs were infused to patients using interventional method via hepatic artery for one group. after the catheter placed at proper hepatic artery was confirmed by angiography, umbilical cord mscs were infused slowly for 15-20minutes. the control group accepted conserved therapy.

Eligibility criteria:
inclusion criteria: * aged 18\~70 years. * liver cirrhosis * written consent exclusion criteria: * the end-stage of liver cirrhosis. * severe problems in other vital organs(e.g.the heart,renal or lungs). * hepatocellular carcinoma or other malignancies * pregnancy * sepsis * presence of significant extrahepatic biliary disease (e.g. cbd stone, psc, etc.) * cardiac, renal or respiratory failure * active thrombosis of the portal or hepatic veins

Keywords: liver cirrhosis radiology mesenchymal stem cells umbilical cord
pulmonary hypertension: assessment of cell therapy

Conditions: Hypertension, Pulmonary

Summary: the primary objective is to establish the safety of autologous progenitor cell-based gene therapy of henos in patients with severe pulmonary arterial hypertension(pah) refractory to conventional treatment.

this is a two centre, phase i clinical trial. a total of 18 patients will be studied using an open-label, dose escaling protocol; three patients will be entered into each of the five dosing panels. an additional three patients will be entered into the final dose panel to establish safety at the maximum tolerated dose.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic pulmonary arterial hypertension * familial pah or anorexigen induced pah * specified 6-minute walk distance exclusion criteria: * intra or extra cardiac communication between the right and left sided circulations * hemodynamic instability * left ventricular ejection fraction \< 40% * thromboembolic event or recent hospitalization for worsening right sided heart failure in past 3 months * cvp\>20mmhg at time of research heart catheterization * pregnancy * concurrent hepatitis or hiv

Keywords: pulmonary arterial hypertension (pah)
evaluation of "beauty drink" on regulation of blood pressure effect by clinical trial

Conditions: Hypertension

Summary: this report assesses the effect of supplementation with gamma-aminobutyric acid on blood pressure among people with mild hypertension. overall, "beauty drink" consumption for 8 weeks could successfully reduce mean diastolic and systolic bp through the suppression of ace linked to downstream suppression of angiotensin ii formation, which further decreases the sympathetic outflow leads to hypertension.

this report assesses the effect of supplementation with gamma-aminobutyric acid on blood pressure among people with mild hypertension. fifty subjects with systolic blood pressure (sbp) between 120 and 159 mm hg and/or diastolic blood pressure (dbp) between 80 and 99 mm hg were randomized to ingest 2 bottles of "beauty drink" or placebo per day for 8 weeks of a stage. in addition, anthropometric measurements (blood pressure, body weight, body fat) and blood biochemical markers including fasting blood glucose (fbg), albumin, total cholesterol (tc), triglyceride (tg), hdl-c, ldl-c, creatinine (cr), blood urea nitrogen (bun), ast, alt were examined every four weeks.

Eligibility criteria:
inclusion criteria: * eligible subjects were untreated hypertensive men or women aged between 20 and 70 years old with sbp between 120 and 159 mmhg and/or dbp between 80 and 99 mmhg as measured in a sitting position exclusion criteria: * subjects were excluded if they had a history of major cardiovascular disease or severe liver dysfunction; diastolic blood pressure ≥ 100 mmhg or systolic blood pressure ≥ 160 mmhg; * alcoholic; * us-controlled diabetics; * stoke in past one year; * mental diseases or melancholia; * pregnancy or breast-feeding a child; * renal dysfunction;

Keywords: gamma-aminobutyric acid blood pressure clinical trial angiotensin converting enzyme beauty drink